Introduction
Acute heart failure (AHF) is often triggered by identifiable factors, such as non-compliance with medication or diet, severe hypertension, acute coronary syndromes, arrhythmias, volume overload, and systemic inflammation. 1, 2 Systemic inflammation has long been recognized as an important aggravating factor contributing to AHF. [3] [4] [5] However, the impact of inflammation on clinical outcomes in AHF patients remains unclear. C-reactive protein (CRP) is an acute-phase reactant and a nonspecific marker of systemic inflammation, originally described in 1930 . 6 C-reactive protein is currently the most adequate marker for evaluating systemic inflammation, and is widely used in daily clinical practice. 7, 8 In addition, the prognostic importance of CRP has been established in patients with chronic congestive heart failure. [9] [10] [11] Several studies have revealed elevated CRP levels in patients with chronic heart failure, and increasing levels have been associated with higher morbidity and mortality. [12] [13] [14] In contrast, the prognostic value of CRP in patients with AHF has not been fully established. Previous studies suggested an association between elevated CRP levels and increased mortality in patients with AHF. [15] [16] [17] [18] [19] However, these studies were not designed to detect the effect of CRP levels on overall or cardiac-related mortality. Furthermore, few AHF studies have collected data on post-discharge long-term outcomes, and the association between CRP levels and the timing of death is unclear. The usefulness of CRP level as a risk marker in the prognosis of AHF is challenged by the possible confounding effect of an acute-phase response associated with concomitant infection, a factor often underlying acute decompensation. These conditions may affect short-term mortality from non-cardiac causes, such as severe pneumonia, sepsis, and acute respiratory distress syndrome. It is therefore crucial to investigate the short-and long-term cardiac and non-cardiac prognostic values of CRP levels to assess their value as a measurable risk factor in AHF patients. We aimed to analyse the association between CRP levels at admission and times to all-cause, cardiac, and non-cardiac deaths in patients hospitalized for AHF. These patients were evaluated using data from a relatively large, multicentre, prospective AHF cohort, the Acute Decompensated Heart Failure Syndromes (ATTEND) study.
Methods

Study overview
The ATTEND study has previously been described in detail, 20, 21 and is briefly summarized here. The ATTEND study was a nationwide, observational, hospital-based, multicentre, prospective cohort study conducted in Japan, aiming to clarify the clinical picture in patients with AHF, including their demographic characteristics, clinical profiles, and outcomes. The ATTEND study collected conventional information within the scope of daily clinical practice, with no additional specific examinations or interventions. The study protocol has been approved by the ethics committee at each participating centre, and written informed consent was obtained from all the study patients.
Patients
The patient cohort for the ATTEND study included patients admitted to hospital with AHF. The diagnosis of heart failure was made on the basis of modified Framingham criteria, requiring the presence of 2 major criteria or 1 major and 2 minor criteria. 20 AHF was defined as new-onset decompensated heart failure or exacerbation of chronic compensated heart failure meeting the above criteria and requiring acute hospitalization.
Patients were eligible for inclusion in the study if the primary cause of admission was an episode of AHF. On hospitalization, eligible patients were recruited and data were compiled on a per-patient basis. Persons aged <20 years were excluded from the study. We also excluded patients with chest symptoms such as chest pain, ischaemic changes on electrocardiography, and patients in whom serum cardiac markers indicated a diagnosis of acute coronary syndrome.
Study setting
The ATTEND study investigators prospectively registered 4842 patients hospitalized for AHF throughout Japan between 1 April 2007 and 31 December 2011. At the time of admission, CRP levels were measured locally at each site using a clinically validated high-sensitivity assay. Of the 4842 patients registered, 65 patients with missing CRP measurements were excluded, leaving the measurements from 4777 patients (98.7%) for analysis ( Figure 1 ). The characteristics of the patients excluded because of missing CRP levels were similar to the remainder of the cohort, with no significant differences in terms of cardiac and non-cardiac outcomes (P ¼ 0.402 and P ¼ 0.244, respectively). 
Statistical analysis
Analyses were performed using SAS system version 9.4 (SAS Institute, Cary, NC, USA) at an independent biostatistics and data centre (STATZ Institute, Inc., Tokyo, Japan 
Results
Baseline characteristics
The median CRP level in this study was 5.8 mg/L, with an intertertile range of 2.9-11.8 mg/L. Patients were divided into tertiles based on CRP level at admission (Figure 1) , and the baseline demographic and clinical characteristics of the study population according to CRP tertiles are shown in Figure 2 . There were significant increases in all-cause, cardiac, and non-cardiac mortalities from the lowest to highest tertiles of CRP levels measured on admission (log-rank P < 0.001, P < 0.001, and P < 0.001, respectively). Among patents in the third tertile, the cumulative incidence rates of all-cause, cardiac, and non-cardiac death were 34 ) with first-tertile CRP levels as the reference, CRP levels in the third tertile were independently associated with higher all-cause mortality (adjusted HR, 1.78; 95% CI, 1.50-2.10; P < 0.001), cardiac mortality (adjusted HR, 1.43; 95% CI, 1.15-1.78; P ¼ 0.001), and non-cardiac mortality (adjusted HR, 2.49; 95% CI, 1.89-3.27; P < 0.001). CRP levels in the second tertile were also independently associated with higher all-cause mortality (adjusted HR, 1.30 ; 95% CI, 1.09-1.54; P ¼ 0.004), and non-cardiac mortality (adjusted HR, 1.47; 95% CI, 1.10 to 1.97; P ¼ 0.009). Although CRP levels in the second tertile were associated with higher cardiac mortality in univariable analysis (crude HR, 1.27 ; 95% CI, 1.04-1.55; P ¼ 0.017), they were not independently associated with cardiac death in multivariable analysis (adjusted HR, 1.21 ; 95% CI, 0.97-1.51; P ¼ 0.091), throughout the entire follow-up period. Among CRP and confounders, multicollinearities were not detected in regression diagnostic analysis.
Subgroup analysis
To evaluate the heterogeneity of the association of CRP levels on admission with an increased risk of subsequent mortality, subgroup analyses were performed ( Table 2) . As a result, there were significant interactions in the association of CRP levels with mortality when the patients were stratified by an ischaemic aetiology and left ventricular ejection fraction. The effect of modestly elevated CRP levels (second tertile) at admission on the risk of all-cause mortality after admission for AHFS was significantly greater in the subgroup of patients with an ischaemic aetiology than in those with a non-ischaemic aetiology (P ¼ 0.022 for the interaction). In addition, the effect of markedly elevated CRP levels (third tertile) on the risk of cardiac mortality was significantly greater in the subgroup of patients with an ischaemic aetiology than in those with a non-ischaemic aetiology (P ¼ 0.031 for the interaction). Furthermore, the effect of markedly elevated CRP levels on the risk of cardiac mortality was significantly greater in the subgroup of patients with reduced ejection fraction ( 40%) than in those with preserved ejection fraction (>40%, P ¼ 0.047 for the interaction). However, there was no significant interaction of all-cause, cardiac, and non-cardiac mortality after admission with CRP levels in subgroups stratified by sex.
Mortality according to follow-up periods
Survival curves for all-cause, cardiac, and non-cardiac deaths within 120 days after admission for AHF were similar for patients with CRP levels in the first and second tertiles on admission ( Figure 2) . We therefore produced two sets of Cox adjusted curves according to the follow-up period, for deaths within or after 120 days, respectively ( Figure 3) . For patient deaths within 120 days after admission for AHF, CRP levels in the third tertile were associated with poorer allcause, cardiac, and non-cardiac survival rates compared with patients in the first and second tertiles. Mortalities in the first and second tertiles were similar during this period ( Figure 3A-C) . In contrast, CRP levels in the second tertile were associated with poorer all-cause, cardiac, and non-cardiac survival rates after 120 days compared with the first tertile ( Figure 3D-F) . Interestingly, the rate of cardiac death after 120-days follow-up was higher in the second than in the third tertile group ( Figure 3E ). As shown in Figure 4 (Cox non-proportional hazards model), patients in the third tertile were independently associated with higher all-cause, cardiac, and non-cardiac deaths within 120 days after admission, according to multivariable analysis with first-tertile as the reference. Conversely, patients in the second tertile showed similar survival to those in the first tertile within 120 days after admission. After the 120-day follow-up period, patients in both the third and second tertiles had significantly higher risks of all-cause and non-cardiac deaths according to multivariable analysis. In terms of cardiac deaths, the HR for CRP levels in the third tertile decreased markedly from 120 days after hospitalization, and only CRP levels in the second tertile were independently associated with poorer survival after the 120-day follow-up period ( Figure 4) . In addition, we performed sensitivity analyses adopting a cut-off thresholds (after 60, 90,120, and 150 days) for the stratified analysis, and after 120 days showed the most favourable performance for long-term cardiac death risk stratification in the second tertile group. As for linear trend for continuous CRP level, a linear association was observed for both cardiac mortality (linearity: P < 0.001) and non-cardiac mortality (linearity P < 0.001) within 120 days after admission. In contrast, however, a non-linear association was observed for both cardiac mortality (linearity: P ¼ 0.345) and non-cardiac mortality (linearity P ¼ 0.161) after the 120-day follow-up period ( Figure 4 ).
Discussion
In this study, we clarified the prognostic implications of CRP values in patients with AHF. A relatively high CRP level on admission was a significant predictor of mortality from both non-cardiac and cardiac causes in this relatively large, multicentre, prospective AHF cohort. We also revealed an apparent association between CRP levels on admission and duration of survival after hospitalization in AHF patients. The risks of cardiac and non-cardiac deaths among patients with the highest CRP tertile were markedly higher up to 120 days after hospitalization compared with after 120 days, while the risks of cardiac and non-cardiac deaths in patients in the second tertile increased after 120 days, compared with those in the first tertile. Prognostic assessments in individual AHF patients have been challenging because of considerable variabilities in the clinical course of AHF.
1,2,24, 25 The results of this study thus importantly support the use of a widely available, simple, and inexpensive parameter for risk stratification of AHF patients. We demonstrated a non-linear increase in short-term mortality in relation to CRP levels, with additional risk being exclusive to patients with markedly elevated CRP levels (third tertile). Patients with CRP measurements in the upper tertile (>11.8 mg/L) on admission should thus treated with great caution, given the significantly increased risk of short-term mortality. This cutoff value for CRP levels was higher than the 3 mg/L proposed for the general population and for patients with stable coronary heart disease, 26 and is consistent with previous studies on AHF patients from Spain, Finland, and Portugal (cut-off CRP levels >9 mg/L, >10 mg/L, and >12.3 mg/L, respectively). 15, 18, 19 This apparently higher cut-off value for short-term mortality may not be surprising given that AHF occurs in patients with an acute-phase response (i.e. exacerbation of an inflammatory condition). In addition, these findings suggest that the severity of the acute-phase response may be correlated with the extent of the acute systemic inflammatory response quantified by markedly elevated CRP levels (about >10 mg/L) and short-term mortality during an early 'vulnerable phase' after hospitalization for AHF. A previous study by Alonso-Martinez et al. 15 evaluated 76 hospitalized patients with AHF and reported that patients with higher CRP levels (>9 mg/L) on admission had higher readmission rates and shorter periods before readmission. In a larger multicentre study including 620 patients hospitalized with AHF, Siiril€ a-Waris et al. 18 found an almost two-fold increased risk of death during a 1-year follow-up period in patients with CRP levels >10 mg/L on admission.
The same association between increased CRP levels and poor outcomes has been reported by numerous other groups, 16, 17, 19 including two studies that excluded infected patients. 16, 19 Similarly the ATTEND study only included patients in whom an episode of AHF was the primary cause of admission, and excluded patients with severe concomitant infections as the primary cause of admission. However, only obvious, severe infections on admission were considered, and the possibility that some patients may have had undetected infectious diseases cannot be discarded. We therefore analysed cardiac and non-cardiac mortalities separately in the AHF setting, in addition to exclude patients with severe concomitant infection as the primary cause of admission. As a result, patients with higher CRP levels were associated with increased risks of both cardiac and non-cardiac deaths in this study. The exclusion of patients with obvious infectious diseases as the primary cause of admission, and separate analyses of cardiac and non-cardiac deaths allowed us to overcome the potential biases and thus determine the prognostic importance of CRP levels on admission in patients with AHF. In this analysis, modestly elevated CRP levels (second tertile) on admission (2.9-11.8 mg/L) were associated with poorer survival, and especially with a higher cardiac death rate, after 120 days from admission in patients hospitalized for AHF. A previous study also revealed that modestly elevated CRP levels (>3.23 mg/L) were associated with features of more severe heart failure, and were independently associated with long-term morbidity and mortality. 9 CRP levels >3 mg/L thus reflect a chronic systemic inflammatory status and indicate a higher long-term cardiovascular risk in patients with heart failure. 27 Our results and those of previous studies may confirm the significance of acute reactive proteins or cytokines in the pathogenesis of heart failure. [3] [4] [5] Considerable evidence suggests that chronic activation of the immune system occurs during heart failure, and some patients present with evidence of monocyte-macrophage and lymphocyte activation. [28] [29] [30] [31] Although the factor responsible for triggering this chronic immune response is unknown, the reninangiotensin-aldosterone system and the sympathetic nervous system are possible candidates. [29] [30] [31] In addition, invasive assessments in 17 patients with AHF revealed higher levels of bacterial endotoxin in the hepatic veins compared with the left ventricle, 4 suggesting that mesenteric hypo-perfusion during heart failure results in bacterial or endotoxin translocation from the bowel into the blood stream. Taken together, these findings support a correlation of heart failure severity with mesenteric hypo-perfusion and the extent of bacterial or endotoxin translocation from the bowel into the blood stream, which in turn correlates with the extent of the chronic systemic inflammatory response quantified by modestly elevated CRP levels (about 3-10 mg/L) and long-term cardiac mortality. 4, 32, 33 These findings also suggest that immune modifications are not an epiphenomenon in patients with heart failure, but play an important role in its pathophysiology. The importance of chronic immune activation and resultant inflammation quantified by CRP levels (3-10 mg/L) in the setting of AHF may help to guide the development of novel immunomodulating and anti-inflammatory therapies, such as statins. [34] [35] [36] [37] Furthermore, patients with modestly elevated CRP levels were associated with smoking and a higher body mass index, indicating that diet, exercise, and smoking cessation may help to prevent chronic inflammation and long-term cardiac events in these patients. We hope that our results will trigger recognition of the significance of the immune system and inflammation in AHF patients, and lead to the adoption of better therapeutic strategies and guidelines for otherwise difficult-to-manage AHF patients with chronic immune activation and 
Limitations
Our study had several limitations. First, it is necessary to consider possible biases that may have affected this study. The analysis of observational data may be limited by the inadequate validity of comparisons, leading to inaccurate interpretations. Despite multivariable analysis, we cannot exclude the possibility that residual measured and/or unmeasured confounders may have influenced our observations. Second, we relied on the clinical evaluations of the attending physicians, and it was often impossible to distinguish between inflammation as the trigger for AHF or its consequence in clinical practice. Third, despite our attempts to exclude patients with severe concomitant infections such as pneumonia as the primary cause of admission, this diagnosis is not always easy to make in elderly patients, and some cases may have not been identified at admission. In addition, the diagnostic criteria for concomitant infections may have differed among different attending physicians. Fourth, we used site-reported CRP levels rather than core laboratory CRP values, because the ATTEND study was not originally designed to detect the relationship between CRP levels and outcomes. While this may have introduced variability in the measurements of CRP levels, the results may be representative of real-world clinical practice.
Conclusions
We conclude that markedly elevated CRP levels (about >10 mg/L) on admission may be associated with increased short-term risks of cardiac and non-cardiac mortalities in patients hospitalized for AHF. In addition, modestly elevated CRP levels (3-10 mg/L) may be associated with poorer long-term (after 120 days follow-up) survival, and especially increased cardiac mortality in these patients. By excluding patients with obvious infectious diseases as the primary cause of admission and by analysing cardiac and non-cardiac deaths separately, we have expanded our knowledge of the short-and long-term prognostic implications of modestly and markedly elevated CRP values, based on a relatively large prospective AHF cohort. Further investigations of the risk stratifications related to CRP levels are needed to improve the management of patients with AHF. 
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